The prototype of glycogen phosphorylase

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 12, 2010, Pages 1093-1101

  Chrysina, E D ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Glycogen phosphorylase; Structure based drug design; Type 2 diabetes; X ray crystallography; D glucopyranosyl analogues

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE;

ALLOSTERISM; ARTICLE; BINDING SITE; CATALYSIS; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; KINETICS; MOLECULARLY TARGETED THERAPY; X RAY CRYSTALLOGRAPHY;

EID: 78549274015     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557511009011093     Document Type: Article

References (67)

1. Zimmet, P.; Alberti, K.G.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature, 2001, 414, 782-787.
2. Stolar, M.W.; Hoogwerf, B.J.; Gorshow, S.M.; Boyle, P.J.; Wales, D.O. Managing type 2 diabetes: going beyond glycemic control. J. Manag. Care Pharm., 2008, 14, s2-19.
3. Blonde, L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleveland Clin. J. Med., 2009, 76(Suppl 5), S4-S11.
4. DeFronzo, R.A. Overview of newer agents: where treatment is going. The American Journal of Medicine, 2010, 123, S38-S48.
5. Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Ferrannini, E.; Holman R.R.; Sherwin, R.; Zinman, B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 2009, 32, 193-203.
6. Rodbard, H.W.; Jellinger, P.S.; Davidson, J.A.; Einhorn, D.; Garber, A.J.; Grunberger, G.; Handelsman, Y.; Horton, E.S.; Lebovitz, H.; Levy, P.; Moghissi, E.S.; Schwartz, S.S. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr. Pract., 2009, 15, 541-559.
7. Scheen, A.J. Drug interactions of clinical importance with anti-hyperglycaemic agents: an update. Drug Saf., 2005, 28, 601-631.
8. Agius, L. New hepatic targets for glycaemic control in diabetes. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 587-605.
9. Bollen, M.; Stalmans, W. The structure, role, and regulation of type 1 protein phosphatases. Crit. Rev. Biochem. Mol. Biol., 1992, 27, 227-281.
10. Sprang S.R.; Acharya, K.R.; Goldsmith, E.J.; Stuart, D.I.; Varvill, K.; Fletterick, R.J.; Madsen, N.B.; Johnson, L.N. Structural changes in glycogen phosphorylase induced by phosphorylation. Nature, 1988, 336, 215-221.
11. Barford, D.; Johnson, L.N. The allosteric transition of glycogen phosphorylase. Nature, 1989, 340, 609-616.
12. Barford, D.; Hu, S.H.; Johnson, L.N. Structural mechanism for glycogen phosphorylase control by phosphorylation and AMP. J. Mol. Biol., 1991, 218, 233-260.
13. Acharya, K.R.; Stuart, D.I.; Varvill, K.M.; Johnson, L.N. Glycogen phosphorylase b: Description of the protein structure; World Scientific Publishing Co. Pte. Ltd: Singapore, 1991.
14. Sprang, S.R.; Withers, S.G.; Goldsmith, E.J.; Fletterick, R.J.; Madsen, N.B. Structural basis for the activation of glycogen phosphorylase b by adenosine monophosphate. Science, 1991, 254, 1367-1371.
15. Johnson, L.N. Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J., 1992, 6, 2274-2282.
16. Johnson, L.N.; Hu, S.H.; Barford, D. Catalytic mechanism of glycogen phosphorylase. Faraday Discuss., 1992, 93, 131-142.
17. Oikonomakos N.G. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr. Protein Pept. Sci., 2002, 3, 561-586.
18. Somsák, L.; Czifrák, K.; Tóth, M.; Bokor, E.; Chrysina, E.D.; Alexacou, K.-M.; Hayes, J.M.; Tiraidis, C.; Lazoura, E.; Leonidas, D.D.; Zographos, S.E.; Oikonomakos, N.G. New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr. Med. Chem., 2008, 15, 2933-2983.
19. Johnson, L.N. The regulation of protein phosphorylation. Biochem. Soc. Trans., 2009, 37, 627-641.
20. Oikonomakos, N.G.; Skamnaki, V.T.; Tsitsanou, K.E.; Gavalas, N.G.; Johnson, L.N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure, 2000, 8, 575-584.
21. Chrysina, E.D.; Kosmopoulou, M.N.; Tiraidis, C.; Kardakaris, R.; Bischler, N.; Leonidas, D.D.; Hadady, Z.; Somsák, L.; Docsa, T.; Gergely, P.; Oikonomakos, N.G. Kinetic and crystallographic studies on 2-(β-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. Protein Sci., 2005, 14, 873-888.
22. Treadway, J.L.; Mendys, P.; Hoover, D.J. Glycogen phosphorylase inhibitors for the treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs, 2001, 10, 439-454.
23. McCormac, J.G.; Westergaard, N.; Kristiansen, M.; Brand, C.L.; Lau, J. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr. Pharm. Des., 2001, 14, 1451-1474.
24. Kurukulasuriya, R.; Link, J.T.; Madar, D.J.; Pei, Z.; Richards, S.J.; Rohde, J.J.; Souers, A.J.; Szczepankiewicz, B.G. Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. Curr. Med. Chem., 2003, 10, 123-153.
25. Lu, Z.; Bohn, J.; Bergeron, R.; Deng, Q.; Ellsworth, K.P.; Geissler, W.M.; Harris, G.; McCann, P.E.; McKeever, B.; Myers, R.W.; Saperstein, R.; Willoughby, C.A.; Yao, K.; Chapman, K. A new class of glycogen phosphorylase inhibitors. Bioorg. Med. Chem., 2003, 13, 4125-4128.
26. Kristiansen, M.; Andersen, B.; Iversen, L.F.; Westergaard, N. Identification, sythesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site. J. Med. Chem., 2004, 47, 3537-3545.
27. Henke, B.R.; Sparks, S.M. Glycogen phosphorylase inhibitors. Mini Rev. Med. Chem., 2006, 6, 845-857.
28. Oikonomakos, N.G.; Somsák, L. Advances in glycogen phosphorylase inhibitor design. Curr. Opin. Investig. Drugs, 2008, 9, 379-395.
29. Klein H.W.; Im M.J.; Helmreich E.J.M. Chemical & Biological aspects of Vitamin B6 Catalysis. Evangelopoulos, A.E. Ed. Part A., Liss, New York 1984; pp. 147-160.
30. Palm D.; Klein H.W.; Schinzel R.; Buehner M.; Helmreich, E.J.M. The role of pyridoxal 5'-phoshpate in glycogen phosphorylase catalysis. Biochemistry, 1990, 29, 1099-1107.
31. Oikonomakos N.G.; Acharya K.R.; Johnson L.N. Rabbit muscle glycogen phosphorylase b. The structural basis of activation and catalysis. Harding, J.J.; James, M.; Crabbe, C. Eds. CRC Press, Boca Raton, Florida 1992; pp. 81-151.
32. Watson K.A.; McCleverty C.; Geremia S.; Cottaz S.; Driguez H.; Johnson, L.N. Phosphorylase recognition and phosphorolysis of its oligosaccharide substrate: answers to a long outstanding question. EMBO J., 1999, 18(17), 4619-4632.
33. Martin J.L.; Veluraja, K.; Ross, K.; Johnson, L.N.; Fleet, G.W.J.; Ramsden, N.G.; Bruce, I.; Orchard, M.; Oikonomakos, N.G.; Papageorgiou, A.C.; Leonidas, D.D.; Tsitoura, H.S. Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry, 1991, 30, 10101-10116.
34. Watson, K.A.; Mitchell, E.P.; Johnson, L.N.; Cruciani, G.; Son, J.C.; Bichard, C.J.F.; Fleet, G.W.J.; Oikonomakos, N.G.; Kontou, M.; Zographos, S.E. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID Force-Field and GOLPE variable selection. Acta Crystallogr. D Biol. Crystallogr., 1995, 51, 458-472.
35. Chrysina, E.D.; Oikonomakos, N.G.; Zographos, S.E.; Kosmopoulou, M.N.; Bischler, N.; Leonidas, D.D.; Kovács, L.; Docsa, T.; Gergely, P.; Somsák, L. Crystallographic studies on α-and β-D-glucopyranosyl formamide analogues, inhibitors of glycogen phosphorylase. Biocatal., Biotransformation, 2003, 21, 233-242.
36. Chrysina, E.D.; Kosmopoulou, M.N.; Kardakaris, R.; Bischler, N.; Leonidas, D.D.; Kannan, T.; Loganathan, D.; Oikonomakos, N.G. Binding of β-D-glucopyranosyl bismethoxyphosphoramidate to glycogen phosphorylase b. Kinetic and crystallographic studies. Bioorg. Med. Chem., 2005, 13, 765-772.
37. Somsák, L.; Nagy, V.; Hadady, Z.; Docsa, T.; Gergely, P. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: Recent developments. Curr. Pharm. Des., 2003, 9, 1177-1189.
38. Somsák, L.; Kovács, L.; Tóth, M.; sz, E.; Szilágyi, L.; Györgydeák, Z.; Dinya, Z.; Docsa, T.; Tóth, B.; Gergely, P. Synthesis of and a comparative study of the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of D-gluco and D-xylopyranosylidene-spiro-(thio)hydantoins and N-(D-glucopyranosyl)amides. J. Med. Chem., 2001, 44, 2843-2848.
39. Györgydeák, Z.; Hadady, Z.; Felföldi, N.; Krakomperger, A.; Nagy, V.; Tóth, M.; Brunyánszki, A.; Docsa, T.; Gergely, P.; Somsák, L. Synthesis of N-(β-D-glucopyranosyl)- and N-(2-acetamido- 2-deoxy-β-D-glucopyranosyl) amides as inhibitors of glycogen phosphorylase. Bioorg. Med. Chem., 2004, 12, 4861-4870.
40. Petsalakis, E.I.; Chrysina, E.D.; Tiraidis, C.; Hadjiloi, T.; Leonidas, D.D.; Oikonomakos, N.G.; Aich, U.; Varghese, B.; Loganathan, D. Crystallographic studies on N-azidoacetyl-β-D-glucopyrano-sylamine, an inhibitor of glycogen phosphorylase: comparison with N-acetyl-β-D-glucopyranosylamine. Bioorg. Med. Chem., 2006, 14, 5316-5324.
41. Czifrák, K.; Hadady, Z.; Docsa, T.; Gergely, P.; Schmidt, J.; Wessjohann, L.; Somsák, L. Synthesis of N-(β-D-glucopyranosyl) monoamides of dicarboxylic acids as potential inhibitors of glycogen phosphorylase. Carbohydr. Res., 2006, 341, 947-956.
42. Oikonomakos, N.G.; Kosmopoulou, M.N.; Zographos, S.E.; Leonidas, D.D.; Chrysina, E.D.; Somsák, L.; Nagy, V.; Praly, J-P; Docsa, T.; Tóth, B.; Gergely, P. Binding of N-acetyl-N'-β-D-glucopyranosyl urea and N-benzoyl-N'-β-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies. Eur. J. Biochem., 2002, 269, 1-13.
43. Hadjiloi, T.; Tiraidis, C.; Chrysina, E.D.; Leonidas, D.D.; Oikonomakos, N.G.; Tsipos, P.; Gimisis, T. Binding of oxalyl derivatives of β-D-glucopyranosylamine to muscle glycogen phosphorylase b. Bioorg. Med. Chem., 2006, 14, 3872-3882.
44. Oikonomakos, N.G.; Kontou, M.; Zographos, S.E.; Watson, K.A.; Johnson, L.N.; Richard, C.J.; Fleet, G.W.; Acharya, K.R. N-acetyl-β-D-glucopyranosylamine: a potent T-state inhibitor of glycogen phosphorylase. A comparison with α-D-glucose. Protein Sci., 1995, 4, 2469-2477.
45. Anagnostou, E.; Kosmopoulou, M.N.; Chrysina, E.D.; Leonidas, D.D.; Hadjiloi, T.; Tiraidis, C.; Zographos, S.E.; Gyorgydeák, Z.; Somsák, L., Docsa, T.; Gergely, P., Kolisis, F.N.; Oikonomakos, N.G. Crystallographic studies on two bioisosteric analogues, N-acetyl-β-D-glucopyranosylamine and N-trifluoroacetyl-β-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase. Bioorg. Med. Chem., 2006, 14, 181-189.
46. Czakó, Z.; Juhász, L.; Kenéz, A.; Czifrák, K.; Somsák, L.; Docsa, T.; Gergely, P.; Antus, S. Synthesis and glycogen phosphorylase inhibitory activity of N-(β-D-glucopyranosyl)amides possessing 1,4-benzodioxane moiety. Bioorg. Med. Chem., 2009, 17, 6738-6741.
47. Tóth, M.; Kun, S.; Bokor, E.; Benltifa, M.; Tallec, G.; Vidal, S.; Docsa, T.; Gergely, P.; Somsák, L.; Praly, J-P. Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as inhibitors of glycogen phosphorylase. Bioorg. Med. Chem., 2009, 17, 4773-4785.
48. Felföldi, N.; Tóth, M.; Chrysina, E.D.; Charavgi, M-D.; Alexacou, K-M; Somsák, L. Synthesis of new glycosyl biuret and urea derivatives as potential glycoenzyme inhibitors. Carbohydr. Res., 2010, 345, 208-213.
49. Benltifa, M.; Vidal, S.; Gueyrard, D., Goekjian, P.G., Msaddek, M., Praly, J.-P. 1,3-dipolar cycloaddition reactions on carbohydrate-based templates: synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhbitors. Tetrahedron Lett., 2006, 47, 6143-6147.
50. Chrysina, E.D.; Bokor, E.; Alexacou, K-M.; Charavgi, M-D.; Oikonomakos, N.G.; Zographos, S.E.; Leonidas, D.D.; Oikonomakos, N.G.; Somsák, L. Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case. Tetrahedron Asymmetry, 2009, 20, 733-740.
51. Watson, K.A.; Chrysina, E.D.; Tsitsanou, K.E.; Zographos, S.E.; Archontis, G.; Fleet, G.W.; Oikonomakos, N.G. Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase. Proteins, 2005, 61, 966-983.
52. Archontis, G.; Watson, K.A.; Xie, Q.; Andreou, G.; Chrysina, E.D.; Zographos, S.E.; Oikonomakos, N.G.; Karplus, M. Glycogen phosphorylase inhibitors: a free energy perturbation analysis of glucopyranose spirohydantoin analogues. Proteins, 2005, 61, 984-998.
53. Krulle, T.M.; delaFuente, C.; Watson, K.A.; Gregoriou, M.; Johnson, L.N.; Tsitsanou, K.E.; Zographos, S.E.; Oikonomakos, N.G.; Fleet, G.W.J. Synlett., 1997, 2, 211-213.
54. Gregoriou, M.; Noble, M.E.; Watson, K.A.; Garman, E.F.; Krulle, T.M., de la Fuente, C.; Fleet, G.W.; Oikonomakos, N.G.; Johnson, L.N. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 Å resolution and 100 K; the role of the water structure and its contribution to binding. Protein Sci., 1998, 7, 915-927.
55. Benltifa, M.; Hayes, J.M.; Vidal, S.; Gueyrard, D.; Goekjian, P.G.; Praly, J.P., Kizilis, G.; Tiraidis, C.; Alexacou, K.M.; Chrysina, E.D.; Zographos, S.E.; Leonidas, D.D.; Archontis, G.; Oikonomakos, N.G. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors. Bioorg. Med. Chem., 2009, 17, 7368-7380.
56. Nagy, V.; Benltifa, M.; Vidal, S.; Berzsenyi, E.; Teilhet, C.; Czifrak, K.; Batta, G.; Docsa, T.; Gergely, P.; Somsak, L.; Praly, J.-P. Glucose-based spiro-heterocycles as potent inhibitors of glycogen phosphorylase. Bioorg. Med. Chem., 2009, 17, 5696-5707.
57. Board, M.; Bollen, M.; Stalmans, W.; Kim, Y.; Fleet, G.W.J.; Johnson, L.N. Effects of C-1-substituted glucose analogue on the activation states of glycogen synthase and glycogen phosphorylase in rat hepatocytes. Biochem. J., 1995, 311, 845-852.
58. Zographos, S.E.; Oikonomakos, N.G.; Tsitsanou, K.E.; Leonidas, D.D.; Chrysina, E.D.; Skamnaki, V.T.; Bischoff, H.; Goldmann, S.; Watson, K.A.; Johnson, L.N. The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure, 1997, 5, 1413-1425.
59. Pinotsis, N.; Leonidas, D.D.; Chrysina, E.D.; Oikonomakos, N.G.; Mavridis, I.M. The binding of β- and γ-cyclodextrins to glycogen phosphorylase b: kinetic and crystallographic studies. Protein Sci., 2003, 12, 1914-1924.
60. Mayer, M; Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc., 2001, 123, 6108-6117.
61. Gozalbes, R.; Carbajo, R.J.; Pineda-Lucena, A. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. Curr. Med. Chem., 2010, 17, 1769-1794.
62. Emiris, I.Z.; Nikitopoulos, T.G. Molecular conformation search by distance matrix perturbations. J. Math. Chem., 2005, 37, 233-253.
63. Papaioannou G.; Karabassi, E.A.; Theoharis, T. Reconstruction of three-dimensional objects through matching of their parts. IEEE Trans. Pattern Anal. Mach. Intell. (TPAMI), 2002, 24, 114-124.
64. Johnson, L.N.; Hajdu, J.; Acharya, K.R.; Stuart, D.I.; McLaughlin, P.J.; Oikonomakos, N.G.; Barford, D. Glycogen phosphorylase b. In Allosteric Enzymes, Herve, G. Ed. CRC Press, Baca Raton, Florida 1989; pp. 81-127.
65. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25, 1605-1612.
66. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. Appl. Crystallogr., 1991, i, 946-950.
67. Merritt, E.A.; Bacon, D.J. Raster3D: Photorealistic molecular graphics. Methods Enzymol., 1997, 277, 505-524.